Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 12, 2022 08:30 ET | Source: Tenax Therapeutics

Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjects with Any Health Condition Patent Term to 2039, Exclusive of Any Possible Extensions MORRISVILLE, N.C., Jan. 12, 2022...
January 04, 2022 08:30 ET | Source: Tenax Therapeutics

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

Receives a Notice of Allowance of Multiple Patent Claims for TNX-102 (subcutaneous levosimendan) Successfully Completes IV to Oral Transition Substudy for TNX-103 (oral levosimendan) Plans to...